Skip to Main Content

Updated on May 23, 2024; new features allow drugs to be filtered by characteristics like development phase and route of administration. Read about a new strategy involving gene silencing here

The blazing success of weight loss drugs like Wegovy and Mounjaro has electrified the pursuit of new treatments for obesity. For now, Novo Nordisk and Eli Lilly are leading the market with injectable drugs that target receptors of the GLP-1 hormone to mimic the hormone’s effects of helping people feel full. But dozens of companies are also jumping into the race, seeing the potential to make millions of dollars if they can bring to market medications that are oral, longer-lasting, avoid side effects, or provide additional benefits besides weight loss.


Many of these drugs are also targeting receptors of GLP-1, as well as other hormones involved in satiety and metabolism, but some are using entirely novel mechanisms.

STAT+ Exclusive Story


This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in



Totals $468 per year

$39/month Get Started

Totals $468 per year



for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month



Save 15%

$399/year Get Started

Save 15%

11+ Users


Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users


Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.


STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.